HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Market News Stocks News ETF News Crypto News

Praxis Precision Medicines, Inc.

Contributing Author

Recent Articles by Praxis Precision Medicines, Inc.

Oct-16
Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering PRAX +16.77% GlobeNewswire
Oct-16
Praxis Precision Medicines, Inc. Announces Proposed Public Offering PRAX GlobeNewswire
Oct-16
Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor PRAX GlobeNewswire
Oct-02
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Sep-04
Praxis Precision Medicines to Participate in September Investor Conferences PRAX GlobeNewswire
Sep-03
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Aug-29
Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-25
Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline PRAX GlobeNewswire
Aug-06
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Aug-05
Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04
Praxis Precision Medicines to Participate in Upcoming Fireside Chat PRAX GlobeNewswire
Aug-04
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results PRAX GlobeNewswire
Aug-04
Praxis Precision Medicines Announces Positive, Best-in-Disease Topline Results in Patients with Focal Onset Seizures from the RADIANT Study of Vormatrigine PRAX GlobeNewswire
Jul-29
Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results PRAX GlobeNewswire
Jul-17
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies PRAX GlobeNewswire
Jul-02
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
Jun-04
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-20
Praxis Precision Medicines to Participate in Upcoming Conferences PRAX GlobeNewswire
May-05
Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event PRAX GlobeNewswire
May-02
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PRAX GlobeNewswire
May-02
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results PRAX GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.